xBxBio's scientific endeavors are driven by the unparalleled expertise of Chief Scientific Officer Kenneth Bean, a seasoned leader with decades of experience in regulatory science and clinical protocol development. As a former Quality Control and Quality Management executive at the U.S. Food & Drug Administration, Bean has played a pivotal role in ensuring the highest standards in pharmaceutical development and regulatory compliance. 

 

Throughout his illustrious career, Bean has been a trusted advisor to some of the most prominent names in the pharmaceutical and biotech industries, including Johnson & Johnson, AbbVie, Valeant Pharmaceuticals, Biogen, Amylin Pharmaceuticals, Boston Scientific, Medimmune, Yamatake, Allergan, and Amgen. His deep understanding of regulatory pathways and clinical research design has made him a sought-after expert for creating and implementing complex FDA clinical protocols.

 

A Ph.D. candidate in Biochemistry through a joint program between the University of Massachusetts and Harvard University, Bean combines advanced scientific knowledge with practical, real-world application. His groundbreaking contributions to technological innovation earned him the prestigious National Medal of Technology and Innovation Award, the highest honor granted by the President of the United States for advancements in science and technology.

 

Bean’s leadership and unmatched expertise are central to xBxBio’s mission to revolutionize drug discovery and clinical research, ensuring the company remains at the forefront of innovation in the life sciences industry.